Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.63 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22209067 | 0.88 | HTT (0.60) | L3MBTL1SMN1; SMN2HPGDHRH1KDM4E | |
| SCHEMBL8714203 | 0.86 | SMN1; SMN2 (0.53) | L3MBTL1SMN1; SMN2HPGDHRH1DRD2 | |
| SCHEMBL5007118 | 0.84 | HTR1A (0.64) | L3MBTL1PTGDR2SMN1; SMN2POLBGLA | |
| SCHEMBL14193733 | 0.83 | L3MBTL1 (0.59) | L3MBTL1PTGDR2SMN1; SMN2POLBGLA | |
| SCHEMBL266662 | 0.81 | L3MBTL1 (0.72) | L3MBTL1PTGDR2SMN1; SMN2POLBGLA | |
| SCHEMBL3409855 | 0.81 | L3MBTL1 (0.67) | L3MBTL1PTGDR2SMN1; SMN2POLBGLA | |
| SCHEMBL503961 | 0.81 | L3MBTL1 (0.77) | L3MBTL1PTGDR2SMN1; SMN2POLBGLA | |
| SCHEMBL9774142 | 0.81 | HRH1 (0.60) | L3MBTL1SMN1; SMN2HPGDHRH1KDM4E | |
| SCHEMBL1332146 | 0.81 | PTGDR2 (0.61) | L3MBTL1PTGDR2SMN1; SMN2POLBGLA | |
| SCHEMBL9275347 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2HPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021021927-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-02-04 | — | — | WO | claimed |
| US-20220304957-A1 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | UNIV LOUISIANA STATE (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2021021927-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020146876-A2 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2020-07-16 | — | — | WO | disclosed |
| US-7414063-B2 | Inhibitors of Akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1848687-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F. Hoffmann-Roche AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | ELI LILLY AND COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-20060178532-A1 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006082010-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | AKT1, AKT2, BRAF | L3MBTL1 1339/4885PTGDR2 4128/4885SMN1; SMN2 2866/4885 |
| US-20060178532-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | L3MBTL1 2543/4885PTGDR2 545/4885SMN1; SMN2 3976/4885 |
| US-20220304957-A1 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MCL1 | L3MBTL1 3945/4885PTGDR2 3584/4885SMN1; SMN2 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.